4DMT THERAPEUTIC VECTOR EVOLUTION

Our Platform

We are pioneering the development of precision genetic medicines based on our proprietary vectors. We believe our customized vectors have the potential to enable targeted delivery, efficient transduction, reduced inflammation and resistance to pre-existing antibodies. As a result, we believe we will be able to develop genetic medicines with improved therapeutic profiles and also address previously untreatable diseases and patient populations.

Our Approach

Our Therapeutic Vector Evolution platform enables our “disease specific” approach to product discovery, design and development. We use our platform to discover custom and proprietary vectors designed for specific tissues and diseases, which we believe will allow us to overcome known limitations of conventional AAV vectors and potentially address a broad range of both rare and large market diseases. Based on our Target Vector Profile for a disease, we select customized capsids in non-human primates from an estimated over one billion vector capsid sequences in our 37 proprietary and diverse vector libraries. We subsequently characterize each vector through extensive studies in non-human primates and human cell and organotypic tissue assays.

Our Solution
Overcoming Hurdles Facing Conventional Vectors Via

1.

Targeted delivery to specific tissues by routine clinical routes of administration

2.

Improved transduction of target cell types and tissues

3.

Lower toxicity with reduced inflammation

4.

Ability to avoid neutralization by pre-existing antibodies in humans</p

How it works: Through our proprietary Therapeutic Vector Evolution platform, we rigorously screen our vectors to select for the optimal vector for a specific disease, or class of diseases. We focus on discovering and selecting vectors that we believe have the potential to display superiority to conventional vectors.

4DMT THERAPEUTIC VECTOR EVOLUTION ENABLES THE INVENTION OF TARGETED AND EVOLVED VECTORS


*Capsid library placed under varying selective pressures // Actual number of selection rounds varies by target